Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-05

Study Completion Date

2018-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease. Fructose ingestion by the American public has steadily increased since the 1980's, and with it increases in NAFLD, fatty liver hepatitis (NASH), diabetes, obesity, and cardiovascular disease. Foods and beverage in the U.S. are typically sweetened with sucrose (50% glucose and 50% fructose) or high fructose corn syrup (45-58% glucose and 42-55% fructose) (Stanhope, et al., 2009). Research into the role that added fructose plays in the emerging chronic health issues is necessary to affect public policy and provide the connection between fructose and the increasing incidence of these co-morbidities.

There is evidence that gut bacteria contribute to a range of human diseases including those of the liver and gastrointestinal tract. Dietary fructose has been suggested to play a role in the development of these diseases and has been shown to alter gut microbes in animals. If the investigators find that dietary fructose alters bacteria in the human gut, this would suggest a potential targetable link between high fructose diet and disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Dietary Fat When Eaten With Fructose Versus Glucose

NCT01061346

Body Weight Changes

COMPLETED NA

High Fructose Diet, the Gut Microbiome, and Metabolic Health

NCT06329544

MASLD Type 2 Diabetes Obesity

RECRUITING NA

Dietary Fructose on Microbiota and Hepatosteatosis

NCT04898621

Hepatic Steatosis Dietary Fructose Exposure

COMPLETED NA

Fructose Intestinal Gluconeogenesis

NCT07209202

Healthy Participants Obese But Otherwise Healthy Participants

NOT_YET_RECRUITING NA

Effects of Fructose Restriction on Liver Steatosis

NCT03067428

Nonalcoholic Fatty Liver Disease Glucose Metabolism Disorders Endothelial Dysfunction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non- alcoholic fatty liver disease (NAFLD) occurs in 30% of the adult US population (Luther, J., et al., 2015). Eating large amounts of fructose (a dietary sugar) increases liver fat accumulation and worsens NAFLD. In addition, fructose consumption has been shown to greatly increase triglycerides(fat) in the blood after meals, increasing the risk of heart disease,(Stanhope,et al., 2009) insulin resistance and diabetes. Current theories on liver disease caused by consuming fructose focuses on changes in the breakdown of fat by the liver. In experimental animals, fructose feeding changes the bacteria population (microbiota) in the gut, causes NAFLD and NASH, and increases leaking of toxins from the intestine (intestinal permeability) to the blood stream resulting in inflammation.

In humans, fructose consumption rapidly increases liver fat. However, changes in gut microbiota have not been studied. The proposed study will compare the addition of fructose or glucose to the study subjects' usual diet in a crossover design. They will not know which sugar they are receiving.

The Investigators plan to study postmenopausal, moderately obese but healthy women, and moderately obese but healthy men (age 45-70 years) to find out the effect of fructose verses glucose on the bacteria in their stool and inflammation in the bowel. The Investigators hypothesize that adding fructose to the participant's usual diet, compared to glucose, will change stool bacteria composition and the products that the bacteria produce, which may increase intestinal leakage, and increase markers of inflammation in the stool and blood due to this leakage. These changes may contribute to fructose -induced liver disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Double blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucose, Then Fructose

Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.

Group Type EXPERIMENTAL

Fructose Solution (75 Grams)

Intervention Type OTHER

Fructose given in divided doses at breakfast and dinner.

Glucose Solution (75 grams)

Intervention Type OTHER

Glucose given in divided doses at breakfast and dinner.

Fructose, Then Glucose

Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.

Group Type EXPERIMENTAL

Fructose Solution (75 Grams)

Intervention Type OTHER

Fructose given in divided doses at breakfast and dinner.

Glucose Solution (75 grams)

Intervention Type OTHER

Glucose given in divided doses at breakfast and dinner.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fructose Solution (75 Grams)

Fructose given in divided doses at breakfast and dinner.

Intervention Type OTHER

Glucose Solution (75 grams)

Glucose given in divided doses at breakfast and dinner.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dextrose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post menopausal female, last menstrual period at least 24 months ago OR male
* Age 45-70
* Willing to consume usual diet with either fructose or glucose added during (2) 16-18 day inpatient stays
* Willing to consume usual diet during 2 week wash-out period at home
* BMI 30.0-39.9
* Willingness not to travel long distances while on study, including wash-out period
* Willingness not to be exposed to new pets while on study including wash-out period

Exclusion Criteria

* Fasting serum triglycerides \>200mg/dl
* Fasting blood glucose \>126mg/dl
* Renal function tests \>2x Upper limit of normal
* Liver Function Tests \> 1.5x Upper limit of normal
* Currently on statins
* Daily use of a cathartic
* Broad spectrum antibiotic use within the past 45 days
* Currently on proton pump inhibitor
* Currently on insulin or oral hypoglycemic agents
* Active viral Hepatitis
* Chronic constipation
* Inflammatory bowel disease
* Chronic diarrhea
* GI resection
* Any evidence of cardiovascular disease on EKG
* History of cardiovascular disease such as coronary artery disease, Coronary Artery Bypass Graft, valve replacement, Myocardial Infarction, stroke / Transient Ischemic attack.
* History of macronutrient malabsorption
* Current smoker. Stopped \< 3 months ago.
* Daily alcohol intake equal to 1.5 oz of 40 proof alcohol.
* HIV positive
* Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data
* Persons taking probiotics

Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes